Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tamoxifen inhibits migration of estrogen receptor-negative hepatocellular carcinoma cells by blocking the swelling-activated chloride current.
|
23042559 |
2013 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the genetic polymorphism in ESR1 may play a role in mediating susceptibility to HCC in Chinese hepatitis B virus carriers.
|
16762623 |
2006 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Discrimination of tumorigenic triazole conazoles from phenobarbital by transcriptional analyses of mouse liver gene expression.
|
19363144 |
2009 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this work we have investigated mRNA expression of wild-type and splice variants of ERα in nontumoral, cirrhotic, and malignant human liver, as well as in HCC cell lines, using an exon-specific reverse transcription polymerase chain reaction (RT-PCR).
|
21348637 |
2011 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also show that transcriptional activity of reporter constructs containing human angiotensinogen gene promoter with nucleoside A at -20 is increased on cotransfection of an expression vector containing human estrogen receptor-alpha coding sequence in human hepatoma cells (HepG2) followed by estrogen treatment.
|
9931090 |
1999 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells.
|
24481452 |
2014 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our hypothesis is based on the fact that liver tissue express ER and its different variants exert multiple functions in various stages of liver disease and participate in an extremely complicated signal transduction process, therefore we believe that the presence of one or more SNPs of ESR1 and ESR2 genes may be related with the increase of risk in developing and the severity of HCC, as well as in the response to different treatments.
|
26804600 |
2016 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured levels of G-protein-coupled estrogen receptor (GPER1) in HCC and nontumor liver tissues from 68 patients by immunohistochemistry.
|
30641053 |
2019 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In order to analyze the associations between estrogen receptor gene alpha polymorphisms and cancers susceptibility, we genotyped six single nucleotide polymorphisms (SNPs) in 163 Caucasian cancer patients--103 breast cancers and 60 other malignancies (colorectal, bladder, hepatocellular carcinoma and acute myeloid leukemia)--and 114 healthy controls using hybridization probes.
|
20383761 |
2010 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that few HCC cases expressed ER (5.6%) and PR (4.5%).
|
29563759 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expression of MTA1 in hepatocellular carcinoma (HCC) and its potential relationship to metastasis and to estrogen receptor alpha (ER-alpha) expression has not been examined, forming the basis for this study.
|
15116322 |
2004 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in estrogen receptor alpha (ESR1) are reported to be associated with the susceptibility to persistent HBV infection, HBV liver cirrhosis and HBV-related hepatocellular carcinoma (HCC).
|
23109139 |
2013 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The pS2 gene is estrogen responsive in hepatocarcinoma cells (HepG2) in the presence of estrogen receptor alpha (ERalpha).
|
12403846 |
2002 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The roles of DEMs like hsa-mir-221 in HCC through interactions with DEGs such as ESR1 and CXCL12 may provide new clues for the diagnosis and treatment of HCC patients.
|
28302149 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a previous experiment, we showed that transient overexpressed estrogen receptor-alpha induced early stage HCC cell line Hep 3B cell apoptosis by increasing the hTNF-alpha gene expression in a ligand-independent manner.
|
16633737 |
2006 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with liver cell dysplasia presented with the same estrogen receptor pattern than patients with hepatocellular carcinoma.
|
9537437 |
1998 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In HCV-associated cirrhosis and HCC the decreased expression of estrogen receptor alfa (ERα) in male patients may explain the worse outcome of HCV infection in men than in women.
|
30349537 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The physiological regulation of Oestrogen receptor α (ERα) and peroxisome proliferator-activated receptor alpha (PPARα) in Hepatocellular carcinoma (HCC) remains unknown.
|
29134746 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aberrant sera DNA methylation of CDH1, DNMT3b and ESR1 gene promoters could be a biomarker in the early diagnosis of HBV-related HCC.
|
26660680 |
2016 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Differences in ligand-activation of estrogen receptor alpha (ER(alpha)) were investigated in human HepG2 liver carcinoma and U2 osteogenic sarcoma cells transfected with wild-type ER (ER-wt) and variants expressing only activation function 1 (ERAF1) or AF2 (ER-AF2).
|
10854714 |
2000 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to investigate whether miR-26a, regulated by a human α-fetoprotein (hAFP) and human telomerase reverse transcriptase (hTERT) dual promoter, could be specifically expressed in liver tumor cells to suppress their growth and to clarify whether estrogen receptor-α (ERα) is regulated by miR-26a and involved in the HCC process.
|
21610700 |
2011 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Our findings suggest that the genetic polymorphism in ESR1 may play a role in mediating susceptibility to HCC in Chinese hepatitis B virus carriers.
|
16762623 |
2006 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The ESR1 gene was identified as a candidate tumor suppressor gene in HCC and further validation is warranted.
|
23695389 |
2013 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our study identified two genetic variants at 6q25.1 newly associated with HCC risk, suggesting ESR1 and estrogen signaling may play a role in mediating susceptibility to HCC in Chinese population.
|
28334234 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, the present study demonstrated that both ERα and β were sufficient to inhibit PPARγ and provide a valuable therapeutic option for the treatment of HCC patients.
|
24126791 |
2013 |